5-异丙基吡唑-3-甲酸乙酯 | 78208-72-7

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-异丙基吡唑-3-甲酸乙酯
• 中文别名: 5-异丙基-1H-吡唑-3-羧酸乙酯；3-异丙基-1-H吡唑-5-甲酸乙酯
• 英文名称: ethyl 3-isopropyl-1H-pyrazole-5-carboxylate
• 英文别名: ethyl 5-propan-2-yl-1H-pyrazole-3-carboxylate
• CAS: 78208-72-7
• 化学式: C₉H₁₄N₂O₂
• mdl: MFCD03232642
• 分子量: 182.222
• InChiKey: ILTUMWMASHHTOQ-UHFFFAOYSA-N

物化性质

• 熔点：
  75°C
• 沸点：
  313.0±30.0 °C(Predicted)
• 密度：
  1.101
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放在密封容器中，并置于阴凉、干燥处。请确保储存地点远离氧化剂。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-isopropyl-1H-pyrazole-5-carboxylate,
Synonyms: Ethyl 5-isopropyl-2H-pyrazole-3-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-isopropyl-1H-pyrazole-5-carboxylate,
CAS number: 78208-72-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14N2O2
Molecular weight: 182.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-异丙基吡唑-3-甲酸乙酯 在 水 、 caesium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 5-isopropyl-2-(2,2,2-trifluoroethyl)pyrazole-3-carboxylic acid
  参考文献：
  名称：

  [EN] MORPHOLIN-PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS MORPHOLINE-PYRIDINE

  摘要：

  本发明涉及以下式（I）的化合物，其中X为CR或N；R为氢、卤素或较低的烷基；L为键，-C（O）-或-C（O）NH-；Ar为苯基或含有一个或两个N原子的五元或六元杂环芳基；R1为卤素、较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基或环烷基；n为0、1、2或3；或其药学适宜的酸加合物，所有外消旋混合物，所有对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍（ADHD）、与压力有关的障碍、精神障碍、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢障碍、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍，以及心血管疾病。

  公开号：

  WO2015165835A1
• 作为产物：
  描述：

  3-甲基-2-丁酮 在 sodium ethanolate 、 一水合肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 28.0h， 生成 5-异丙基吡唑-3-甲酸乙酯
  参考文献：
  名称：

  吡唑衍生物作为烟酸受体的部分激动剂。

  摘要：

  烟酸作为降血脂药显得独特，因为它比其他药物具有更大程度地增加HDL胆固醇水平的潜力。但是，它有一些副作用，其中严重的皮肤潮红是最常见的，并且经常限制患者的依从性。在寻找新的激动剂，用于最近鉴定和克隆的G蛋白偶联的烟酸受体中，我们合成了一系列取代的吡唑-3-羧酸，它们被证明对该受体具有显着的亲和力。通过抑制[（3）H]烟酸与大鼠脾膜的结合来测量亲和力。相对于烟酸的效能和内在活性是通过它们对[（35）S] GTPgammaS与大鼠脂肪细胞和脾膜结合的影响来确定的。有趣的是，大多数化合物是部分激动剂。特别是，证明2-重氮双环[3,3,0（4,8）]八-3,8-二烯-3-羧酸（4c）和5-丙基吡唑-3-羧酸（4f）具有K（i）值约0.15 microM的EC（50）值和约6 microM的EC（50）值，而与烟酸相比，它们的固有活性仅为约50％。活性稍强的是5-丁基吡唑-3-羧酸（4g），K（i）值为0

  DOI：

  10.1021/jm030888c

文献信息

• [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE UTILES EN TANT QU'INHIBITEURS DE PDE4
  申请人：PFIZER LTD

  公开号：WO2005009965A1

  公开（公告）日：2005-02-03

  This invention relates to nicotinamide derivative of general formula (I), in which R1, R2 and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.

  这项发明涉及一般式(I)的烟酰胺衍生物，其中R1、R2和R3具有本文中定义的含义，以及含有这些衍生物并将其用作PDE4抑制剂的组合物。
• Novel pyrazolo[1,5- a ]pyridines as orally active EP 1 receptor antagonists: Synthesis, structure-activity relationship studies, and biological evaluation
  作者：Kentaro Umei、Yosuke Nishigaya、Atsushi Kondo、Kazuya Tatani、Nobuyuki Tanaka、Yasushi Kohno、Shigeki Seto

  DOI：10.1016/j.bmc.2017.03.003

  日期：2017.5

  Novel pyrazolo[1,5-a]pyridine derivatives were designed, synthesized and evaluated as orally active EP1 antagonists for the treatment of overactive bladder. Matched molecular pair analysis (MMPA) allowed the design of a new series of pyrazolo[1,5-a]pyridine derivatives 4-6. Structure-activity relationships (SAR) studies of 4-6 were performed, leading to identification of the nanomolar-level EP1 antagonist

  设计，合成和评价新型吡唑并[1,5-a]吡啶衍生物作为口服活性EP1拮抗剂，用于治疗膀胱过度活动症。匹配的分子对分析（MMPA）允许设计一系列新的吡唑并[1,5-a]吡啶衍生物4-6。进行了4-6的结构-活性关系（SAR）研究，鉴定了纳摩尔水平的EP1拮抗剂4c，在17-苯基trinor前列腺素E2诱导的膀胱收缩模型中，通过十二指肠内（id）给药显示出良好的药理作用在大鼠中。
• [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015050798A1

  公开（公告）日：2015-04-09

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式（I）的化合物，其药物组成物以及使用该药物组成物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• [EN] FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS<br/>[FR] COMPOSÉS DE PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE FUSIONNÉS TRICYCLIQUES UTILISÉS EN TANT QU'AGENTS ANTIVIRAUX
  申请人：NOVARTIS AG

  公开号：WO2019123285A1

  公开（公告）日：2019-06-27

  The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

  该发明提供了如下所述的Formula (I)的化合物，以及包含这些化合物的药用盐、药物组合物和药物组合物，以及使用这些化合物、盐和组合物治疗病毒感染的方法，特别是由乙型肝炎病毒（HBV）引起的感染，并减少与HBV相关的严重病症的发生。
• NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20180319797A1

  公开（公告）日：2018-11-08

  The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及新颖的Formula (I)中的取代吡啶哌唑酮衍生物，其中R1、R2、R3、R4、R5、L、Z和X的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新型化合物的方法，包含上述化合物作为活性成分的药物组合物，以及将这些化合物用作药物的用途。